ALEXANDRIA, La., March 2, 2026 /PRNewswire/ — Life Recovery Systems (LRS) has received an Investigational Device Exemption (IDE) from the US Food and Drug Administration (FDA) for testing of the ThermoSuit System (TSS) in a pivotal trial of ischemic stroke patients. The previous SISCO…
Other News
CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting
MINNEAPOLIS, March 02, 2026 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the schedule of scientific presentations reviewing the science and outcomes of Barostim therapy at the Technology and Heart Failure Therapeutics 2026 (THT) meeting. THT, the annual conference organized by the Cardiovascular Research Foundation® (CRF®), will be held March 2-4, 2026, in Boston, Massachusetts. The presentations include late-breaking clinical data, oral sessions and posters highlighting real-world outcomes, cardiac energetics, hospitalization impact, left ventricular ejection fraction (LVEF) improvements and changes in advanced hemodynamic, respectively. Late-Breaking REBALANCE Registry Data In a late-breaking presentation on Monday, March 2, Dr. Dmitry Yaranov will share, for the first time, data from the REBALANCE Registry, a post-market observational study designed to evaluate real-world data on the safety and benefit of Barostim therapy in the commercial setting. Dr. Yaranov will present the six-month outcomes in over 400 patients enrolled in the registry. Scientific Presentations Featuring Barostim Monday, March 2: Late-Breaking Clinical Science Session 1: Initial Six-Month Outcomes with Baroreflex Activation Therapy from the REBALANCE Registry (Dr. Dmitry Yaranov)Unmasking the Energetic Response Following Acute Titration of Baroreflex Activation Therapy Through Patient-Specific Modeling and Simulation (Dr. Rohan Goswami)Impact of Baroreflex Activation Therapy on Hospitalizations: A Single Center Retrospective Analysis (Dr. Joel Joseph) Tuesday, March 3: Electrical Therapies for Heart Failure: Barostimulation for HFrEF (Dr. Philip Adamson)Abstract Session 8: Heart Failure Reduced Ejection Fraction I Real-World Outcomes of Barostim Baroreflex Activation Therapy in Heart Failure: Analysis of a Large Multi-Institutional Database (Dr. Arvind Bhimaraj)LVEF and Functional Improvement Observed in a Post-Market Registry of Barostim Baroreflex Activation Therapy (Dr. Dmitry Yaranov) CVRx Sponsored Satellite Program CVRx will also host a satellite program on Tuesday, March 3 from 12:15-1:30 p.m. ET in Ensemble CD South, which will include the following presentations: Advances in Evidence with Baroreflex Activation Therapy (Dr. Philip Adamson)Outcomes from the REBALANCE Registry (Dr. Dmitry Yaranov)BREATHE-HF: Impact of Barostim Therapy on Cardiac Hemodynamics (Dr. Gabriel T. Sayer)BENEFIT-HF: Broadening Access to Barostim Therapy (Dr. Farooq Sheikh) During the satellite program, faculty will provide updates on the REBALANCE Registry, the BREATHE-HF trial, and the BENEFIT-HF trial. BREATHE-HF, a large physician-initiated study, is evaluating the impact of Barostim on cardiac hemodynamics. In January, CVRx announced the initiation of the BENEFIT-HF trial, a landmark randomized study supported by CMS Category B IDE coverage. The trial is designed to evaluate the impact of Barostim in a significantly expanded heart failure population, with the primary endpoint as a composite of all-cause mortality and heart failure decompensation events. Enrollment is expected to begin in the first half of 2026. “We are excited by the new data supporting Barostim being featured at THT 2026,” said Kevin Hykes, President and Chief Executive Officer of CVRx. “We are encouraged by the increasing adoption of Barostim by the heart failure community. The accelerating cadence of publications evaluating Barostim’s impact is proof of the positive patient impact and increasing acceptance of Barostim in the heart failure treatment continuum.” About CVRx, Inc.CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com. Forward-Looking StatementsThis press release contains forward-looking statements, including statements regarding the expected enrollment of the BENEFIT-HF clinical trial and anticipated benefits of Barostim therapy. These forward-looking statements speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, our expectations regarding enrollment, the resulting impact of our addressable market and other important factors that could cause actual results, performance or achievements to differ materially from those that are found in “Part I, Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, as such factors may be updated from time to time in our other filings with the Securities and Exchange Commission. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Investor Contact:Mark Klausner or Mike VallieICR Healthcare443-213-0501ir@cvrx.comMedia Contact:Emily MeyersCVRx, Inc.763-416-2853emeyers@cvrx.com
Picard Medical / SynCardia Showcases Leadership in Total Artificial Heart Therapy at Technology and Heart Failure Therapeutics Conference
New data highlight additional benefits beyond survival with the SynCardia Total Artificial Heart and preclinical progress for the next-generation Emperor system New data highlight additional benefits beyond survival with the SynCardia Total Artificial Heart and preclinical progress for the next-generation Emperor system
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug application (IND) for the MAGNITUDE Phase 3 clinical trial of nexiguran ziclumeran (nex-z) for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). “We are very pleased to have aligned with the FDA on the path forward for our MAGNITUDE clinical trial, with measures designed to further enhance patient safety and allow us to continue to investigate nex-z in a broad ATTR-CM population,” said Intellia President and Chief Executive Officer John Leonard, M.D. “With the resolution in January of the clinical hold on our MAGNITUDE-2 Phase 3 trial for patients with hereditary ATTR with polyneuropathy, our attention now turns to completing enrollment in both ongoing trials. We appreciate the FDA’s responsiveness throughout this process and thank the many investigators and patients who are participating in these trials.” The clinical holds on the INDs for MAGNITUDE and MAGNITUDE-2 were imposed by the FDA on October 29, 2025, following the observation of Grade 4 liver transaminases and increased total bilirubin in a patient who was dosed with nex-z in MAGNITUDE that met the trial’s protocol-defined pausing criteria. The company has aligned with the FDA on mitigation measures for MAGNITUDE and MAGNITUDE-2 that include enhanced monitoring of liver laboratory tests, guidance for short-term steroid treatment if elevated liver transaminases are observed in the initial period following dosing and the exclusion of patients with certain liver abnormalities. For MAGNITUDE, additional exclusion criteria are being incorporated for patients with a recent history of cardiovascular instability and those with ejection fraction
Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
WAYNE, Pa., March 02, 2026 (GLOBE NEWSWIRE) — Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that it closed its previously announced upsized public offering on February 27, 2026. The offering consisted of 1,840,000 shares of its common stock, which included the exercise in full of the underwriters’ option to purchase 240,000 additional shares, at a price to the public of $125.00 per share. The aggregate gross proceeds to Palvella from this offering, before deducting underwriting discounts and commissions and offering expenses, were $230.0 million.
Neuro Tech Forum 2026
By partnering with the Neuro Tech Forum, CardiacVascular News gives its audience a front row seat to where neuro innovation is headed. The event convenes founders, researchers, clinicians, and investors who are actively building and backing the next wave of neurotechnology. It is a strong editorial fit for CardiacVascular News’ […]
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies
Spinoff from Novartis AG’s acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platform Lead candidates ATR 1072 and ATR 1086 expected to enter clinical trials for PRKAG2 syndrome and PLN cardiomyopathy, respectively SAN DIEGO, Feb. 27,…
Herz P1 Smart Band 2026: What It Tracks, How It Works, and What Consumers Should Know Before Buying
A 2026 Informational Overview of the Herz P1 Smart Band’s Subscription-Free Health Monitoring Features, Heart Rate and HRV Tracking, Sleep Quality Analysis, Blood Oxygen and SpO2 Sensors, Stress and Temperature Monitoring, 30-Day Battery Life Claims, Companion App Functionality, Pricing Structure, Return Policy Terms, Sensor Technology Explained, Water Resistance Specifications, and What Consumers Should Independently Verify Before Purchasing Any Fitness Tracker or Wearable Health DeviceAkron, OH, Feb. 26, 2026 (GLOBE NEWSWIRE) — This article is for informational purposes only. The Herz P1 Smart Band is a consumer wellness product and is not a medical device. It is not intended to diagnose, treat, cure, or prevent any disease or medical condition. Consumers should consult a qualified healthcare professional before making health decisions based on data from any wearable device. This article contains affiliate links. If you click through and make a purchase, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy or integrity of the information presented. The consumer wearable market continues to expand in 2026, with fitness trackers, smart bands, and health monitoring devices competing for attention across a crowded category. For consumers researching their options, sorting through feature claims, pricing models, and subscription structures can feel overwhelming. The Herz P1 Smart Band is one product that’s entered this space, marketed as a subscription-free wrist-worn health tracker with a long battery life and multi-metric monitoring capabilities. This informational overview examines what the Herz P1 Smart Band offers, how its features are described by the company, what the pricing structure looks like, and what consumers should independently verify before purchasing any fitness wearable in this category. The wearable technology space moves quickly, and product specifications, pricing, and availability can change without notice. Any product details are described as stated by the company and should be verified on the official site and directly with the manufacturer. The Herz P1 Smart Band is a consumer wellness product, not an FDA-cleared or FDA-approved medical device, and health monitoring results are not guaranteed. The information below is compiled from publicly available materials and does not represent clinical evaluation, independent laboratory testing, or editorial endorsement of the product or company. To view the current Herz P1 Smart Band offer (official Herz P1 page), consumers can check the complete product details, pricing, and return policy directly. What the Herz P1 Smart Band Is The Herz P1 Smart Band is a wrist-worn consumer wellness and fitness tracker manufactured by WuzuTech LLC, a company based in Akron, Ohio. The company positions the device as a general wellness tool designed for continuous 24/7 health monitoring. It is not classified as a medical device, and the company’s own health disclaimer states that the product and related services “are for general wellness and fitness purposes only and are not intended to be used as a medical device or to replace professional medical advice, diagnosis, or treatment.” The company states that the Herz P1 Smart Band tracks over 20 health and activity metrics using optical heart rate sensors, motion sensors, and temperature sensors built into the device. Data from the band syncs to the Herz companion app, which is available on both iOS and Android. Per the company’s published materials, the device is a one-time purchase with no recurring subscription fees required to access health data or app features. Wearable products in this category use different pricing and app-access models — some include subscription-based features, while others are offered as one-time purchases. Consumers can verify current access terms on the official product page. Regulatory Classification and General Wellness Wearables In the United States, some consumer wearables are marketed as “general wellness” products. The FDA has published guidance describing its enforcement policy for low-risk general wellness products and how they differ from devices intended for diagnosis or treatment. These products may provide estimates and trend insights related to activity and wellness but aren’t intended to diagnose, treat, cure, or prevent disease. The company markets the Herz P1 Smart Band for general wellness and fitness purposes, and states it is not intended to be used as a medical device or to replace professional medical advice. This means the data it provides — heart rate estimates, sleep pattern approximations, SpO2 readings, and activity metrics — should be understood as trend indicators, not clinical measurements. Consumers should avoid using wearable readings as a substitute for clinical evaluation, especially for medical decisions involving heart conditions, oxygenation concerns, unusual temperature patterns, or sleep disorders. Anyone with specific health concerns should consult a licensed healthcare provider who can recommend appropriate monitoring tools. How the Herz P1 Smart Band Works The company’s materials describe the device as using a combination of sensor technologies to collect biometric and activity data from the wearer’s wrist throughout the day and night. The collected data is transmitted via Bluetooth to the Herz companion app (also referenced as QRing), where it’s organized into reports and insights. Optical Heart Rate Sensors — the company states these continuously monitor heart rate and heart rate variability (HRV), providing data on cardiovascular patterns during both active and resting periods. Motion Sensors — accelerometer technology is described as tracking steps, distance, calories burned, and activity intensity throughout the day. Temperature Sensors — the company’s documentation references continuous skin temperature monitoring, which is described as helping users identify patterns related to recovery and overexertion. Blood Oxygen (SpO2) Monitoring — the device is described as measuring blood oxygen saturation levels, which the company frames as relevant to understanding energy levels and respiratory patterns. Per the company’s website, the band also includes stress tracking capabilities and sleep analysis features that monitor sleep stages and quality metrics overnight. What the Herz P1 Smart Band Tracks Based on publicly available information from the company, the Herz P1 Smart Band is described as monitoring the following categories of health and activity data: Heart Rate and HRV — continuous heart rate monitoring and heart rate variability tracking, which the company describes as useful for understanding recovery and cardiovascular health patterns over time. Sleep Quality and Analysis — the company states the band monitors sleep patterns overnight and provides sleep quality insights through the companion app. Blood Oxygen (SpO2) — the device is described as tracking blood oxygen saturation, with data accessible through the app. Skin Temperature — continuous temperature monitoring is referenced in the company’s feature descriptions. Stress Tracking — the company’s materials describe real-time stress monitoring that shows when the body is under strain and how it recovers. Activity Metrics — steps, distance, and calories burned are described as core tracking features. Women’s Health Insights — the company references menstrual cycle tracking capabilities that provide insights into how the cycle affects energy, sleep, and mood. All tracking capabilities described above come from the manufacturer’s publicly available materials. Wrist-worn consumer wellness devices use sensor technologies that provide estimates and trend data — not clinical measurements. Accuracy can vary based on device fit, skin type, motion, environmental conditions, and individual physiology. Consumers who need medically reliable biometric data should consult with a healthcare provider about appropriate monitoring tools. Pricing and Purchase Structure The Herz P1 Smart Band is sold as a one-time purchase through the company’s official website. Wearable products in this category use different pricing models — some require recurring subscriptions to unlock full feature access, while others include all features with a one-time purchase. The company states the Herz P1 Smart Band doesn’t require a recurring subscription to access its companion app features. According to publicly available information on the official website at the time of publication, pricing may vary based on promotions, bundles, and inventory conditions. Consumers should check the official Herz P1 page to confirm the most current pricing, shipping costs, and policy terms before making any purchase decision. The company’s materials state that the purchase includes the smart band, charging cable, and straps. Additional color bands may be sold separately. The company references a 90-day return policy on its official page. Consumers should verify eligibility requirements, timelines, and return shipping responsibilities directly in the published policy before purchasing. Battery Life, Build Quality, and Design The company states the Herz P1 Smart Band contains a 175 mAh battery and describes the following performance characteristics: Active Use Battery Life — the company states up to 25–30 days of regular use on a single charge. Standby Battery Life — up to 60 days of standby time is referenced in the company’s materials. Charging Time — the company states the device fully recharges in approximately 1 to 1.5 hours. Regarding build quality, the company’s documentation describes the device as constructed from a lightweight zinc alloy frame with a durable nylon strap. The company states the band is water-resistant and sweat-proof, suitable for workouts and daily wear. The company’s official product page references water resistance but advises against swimming or full submersion. The Herz P1 Smart Band is described as available in five color options: Midnight Black, Frosted White, Green Power, Navy Blue, and Rose Mist. Battery life and water resistance claims come from the manufacturer. Actual performance may vary based on notification settings, sensor sampling frequency, Bluetooth connectivity, display behavior, device fit, and environmental conditions. Consumers should check the complete product specifications on the official site before purchasing. Companion App and Data Access The company states that the Herz P1 Smart Band syncs with a companion app available for both iOS and Android. The app is described as providing detailed health and fitness reports, goal-setting features, and progress tracking over time. Per the company’s materials, the app supports over 30 languages. The band also includes offline data storage. The company states that if Bluetooth is disconnected, the device can store health data locally for several days. Once reconnected, stored data syncs automatically with the companion app. Consumers should verify app compatibility with their specific device and operating system version before purchasing. What Consumers Commonly Verify Before Purchasing Based on common consumer research patterns in the wearable technology category, here are areas that prospective buyers typically investigate before purchasing a fitness tracker: Accuracy Expectations: Consumer wellness wearables vary in accuracy across different metrics. No wrist-worn consumer device provides clinical-level precision. The company states its device tracks various metrics, but consumers seeking medically reliable data should consult a healthcare provider. Return Policy Terms: The company references a 90-day return policy on its official page. Consumers should verify the specific terms, conditions, and process for returns directly on the company’s website before purchasing. Company Background: WuzuTech LLC is listed as the manufacturer, based in Akron, Ohio. Consumers can verify the company’s business registration, customer service responsiveness, and fulfillment track record independently. App Functionality: Checking the companion app’s current version, update frequency, and user feedback in the iOS App Store or Google Play Store before purchasing can provide additional perspective on the overall experience. Comparison Shopping: Consumers often compare wearables based on sensor types, sampling frequency, battery life under real-world settings, return policy clarity, app permissions, and whether full feature access requires ongoing fees. Evaluating multiple products across these criteria helps inform a purchasing decision. Water Resistance vs. Waterproofing: The company describes the device as water-resistant and suitable for sweat and splashes but advises against swimming or full submersion. Consumers should understand the difference between water resistance ratings before wearing any device in water. Key Terminology for the Consumer Wearable Category Heart Rate Variability (HRV): HRV measures the time variation between heartbeats. In consumer wellness contexts, it’s commonly used as an indicator of recovery and stress. HRV readings from consumer wearables are estimates and shouldn’t be used for medical diagnosis. Blood Oxygen Saturation (SpO2): SpO2 refers to the percentage of oxygen-carrying hemoglobin in the blood. Consumer wearable SpO2 readings are approximations and aren’t equivalent to pulse oximeter readings obtained in clinical settings. Photoplethysmography (PPG): PPG is the optical sensor technology commonly used in consumer wearables to detect blood volume changes beneath the skin. It’s the foundational technology behind heart rate and SpO2 monitoring in most fitness trackers and smart bands. General Wellness Device: A category described in FDA guidance for products intended to promote a healthy lifestyle. General wellness devices aren’t intended to diagnose, treat, cure, or prevent disease and don’t follow the same regulatory pathway as medical devices. Subscription-Free Model: In the wearable category, some manufacturers require monthly or annual subscriptions to access full data insights and features. Subscription-free models provide full feature access with a one-time purchase. Fitness Tracker vs. Smartwatch: A fitness tracker or smart band typically focuses on health and activity monitoring with a lighter design and longer battery life. Smartwatches generally offer broader app functionality, larger displays, and shorter battery life. The Herz P1 Smart Band falls into the fitness tracker and smart band category. Consumer Questions About the Herz P1 Smart Band Is the Herz P1 Smart Band a medical device? No. The company explicitly states that the Herz P1 Smart Band is a general wellness and fitness product. It isn’t intended to diagnose, treat, cure, or prevent any disease or medical condition. The company’s health disclaimer directs consumers to consult a qualified healthcare professional for medical advice. Who manufactures the Herz P1 Smart Band? The Herz P1 Smart Band is manufactured by WuzuTech LLC, a company based in Akron, Ohio. Consumers can verify the company’s business details and contact information independently. Does the Herz P1 Smart Band require a monthly subscription? The company states that no subscription is required. All health data and app features are described as accessible with the one-time device purchase. Consumers should verify this on the official website, as company policies can change. What phone compatibility does the Herz P1 Smart Band support? The company states the device works with both iOS and Android devices through a free companion app. Consumers should verify specific operating system version requirements before purchasing. How long does the Herz P1 Smart Band battery last? The company states up to 25–30 days of regular use on a single charge, with up to 60 days of standby time. Actual battery performance may vary based on usage patterns and settings. The company states charging takes approximately 1 to 1.5 hours. Is the Herz P1 Smart Band waterproof? The company describes the device as water-resistant and suitable for sweat, rain, and hand-washing. However, the company advises against swimming or fully submerging the device. Consumers should check the specific water resistance rating on the official product page. What metrics does the Herz P1 Smart Band track? The company states the device tracks over 20 health and activity metrics, including heart rate, HRV, SpO2, temperature, sleep quality, stress levels, steps, distance, and calories burned. All accuracy claims come from the manufacturer. Does the Herz P1 Smart Band store data offline? The company states the device can store health data locally for several days if Bluetooth is disconnected. Stored data syncs automatically once Bluetooth is reconnected. What is the return policy for the Herz P1 Smart Band? The company references a 90-day return policy on its official page. Consumers should verify eligibility requirements, timelines, and return shipping responsibilities directly in the published policy before purchasing. How does the Herz P1 Smart Band compare to smartwatches? Smart bands and smartwatches serve different purposes. Smart bands like the Herz P1 generally focus on health and fitness tracking with lighter designs and longer battery life. Smartwatches typically offer broader app ecosystems, larger displays, notification management, and shorter battery life. The right choice depends on individual priorities and what you’re looking for in a wearable. Where can consumers purchase the Herz P1 Smart Band? The company’s official website is the primary direct purchase channel. The product has also been listed on third-party retail platforms. Consumers should verify they’re purchasing from an authorized source. What colors are available for the Herz P1 Smart Band? The company’s materials reference five color options: Midnight Black, Frosted White, Green Power, Navy Blue, and Rose Mist. Availability may vary. Additional Category Context Consumers researching subscription-free fitness trackers often evaluate several areas beyond any single product’s feature list. Understanding how optical wrist sensors estimate heart rate and SpO2, what app privacy and data permissions look like, how battery life performs under real-world conditions, and what return and warranty terms actually require are all part of informed decision-making in this category. This article focuses on those evaluation areas using publicly available product disclosures from the Herz P1 Smart Band manufacturer. Consumers are encouraged to apply the same research approach across any wearable they’re considering. For additional context on the broader Herz P1 product line, a separate informational overview examines the company’s smart ring offering — including its features, pricing, accuracy context, and what consumers should verify before purchasing. Read the full informational analysis here. A separate informational overview also examines the company’s smart scale product, including its 8-electrode BIA sensor technology, body composition metrics, and what consumers should verify about accuracy claims for any home health measurement device. Read the full informational overview here. Both analyses were published for informational purposes and are not endorsements or recommendations. A Consumer Verification Checklist for Any Health-Tracking Wearable Before purchasing any health-tracking wearable — including the Herz P1 Smart Band — consumers can strengthen their decision-making by independently verifying the following areas. This checklist isn’t specific to any single product. It’s a framework that applies across the entire consumer wearable category. Verify the App Name and Developer: Download and check out the companion app before purchasing the hardware. Look at who developed it, when it was last updated, and what the current user feedback looks like. The Herz P1 Smart Band syncs with an app referenced as the Herz app or QRing, available on iOS and Android. Check App Permissions: Before installing any health-tracking app, look at what data permissions it requests. Common requests include Bluetooth, location, health data access, and notification permissions. Understand what data the app collects and how it’s stored or shared. Confirm Data Export Options: Some consumers want to export their health data to share with healthcare providers or use with other platforms. Check whether the companion app allows data export and in what formats before committing to a device ecosystem. Read the Return Policy in Full: Don’t rely on summary language. Read the actual return policy terms, including who pays return shipping, whether the device must be in original packaging, and how refunds are processed. The company states a return policy is available on the official Herz P1 website. Check Warranty Terms: Look at what the warranty covers, how long it lasts, and what the claims process involves. Manufacturer warranties for consumer electronics vary significantly in scope and responsiveness. Understand Sensor Limitations: Consumer wearables use optical sensors (PPG), accelerometers, and temperature sensors that provide estimates — not clinical measurements. Factors like skin tone, tattoos, wrist fit, motion, and environmental temperature can affect reading accuracy across all consumer wearable brands. Clarify Water Resistance vs. Waterproofing: These terms mean different things. Check the specific rating. The Herz P1 Smart Band is described as water-resistant and suitable for sweat and splashes, but the company advises against swimming or full submersion. Test Customer Support Responsiveness: Before purchasing, consider sending a pre-sale question to the company’s support team. Response time and quality can give you a sense of what post-purchase support looks like. Ask About Firmware Updates: Wearable devices often receive firmware updates that can affect performance, features, and battery life. Check whether the manufacturer has a track record of providing updates and how they’re delivered. Confirm Device Compatibility: Verify that your specific phone model and operating system version are compatible with the companion app before purchasing. Compatibility requirements can change with operating system updates. Summary of Key Considerations The Herz P1 Smart Band enters 2026 as a subscription-free consumer wellness wearable in a crowded fitness tracker category. The company’s advertised feature set — including 20+ health metrics, up to 30-day battery life, and no recurring fees — positions it as one option among many for consumers exploring accessible health monitoring. As with any consumer wellness device, prospective buyers should understand that the Herz P1 Smart Band is not a medical device and shouldn’t be used as a substitute for professional medical advice, diagnosis, or treatment. All feature claims, accuracy statements, and performance specifications referenced in this article come from the manufacturer’s publicly available materials and haven’t been independently verified through clinical testing as part of this overview. Consumers interested in the complete product details, current pricing, and return policy can view the current Herz P1 Smart Band offer (official Herz P1 page) directly. Contact Information WuzuTech LLC 839 E Market St, Ste 106 #165 Akron, OH 44305 United States Email: support@wuzutech.com Phone: (866) 479-1629 Website: https://herzp1.com Disclaimers Content and General Wellness Disclaimer: This article is for informational purposes only and does not constitute medical advice, professional health guidance, or a product endorsement. The Herz P1 Smart Band is a consumer wellness product, not a medical device. Statements regarding the product have not been evaluated by the Food and Drug Administration. The device is not intended to diagnose, treat, cure, or prevent any disease or medical condition. Consumers should consult with a qualified healthcare professional before making health-related decisions based on data from any consumer wearable device. All product descriptions, features, and specifications referenced in this article are based on the manufacturer’s publicly available materials and have not been independently verified through clinical testing. Results, Pricing, and Availability Notice: Individual results and experiences with consumer wellness wearables vary based on usage patterns, device fit, individual physiology, environmental conditions, and other factors. No specific outcomes are guaranteed. Pricing referenced in this article reflects publicly available information at the time of publication and is subject to change without notice. Consumers should verify all current pricing, shipping costs, and return policy terms directly on the company’s official website before purchasing. FTC Affiliate Disclosure and Publisher Responsibility: This article contains affiliate links. If you click through these links and make a purchase, a commission may be earned at no additional cost to you. This affiliate relationship does not influence the informational content, accuracy, or editorial independence of this article. The publisher is not responsible for the accuracy of information provided by the manufacturer, changes to the product or its availability, or the consumer’s individual experience with the product or company. Consumers are encouraged to conduct their own research and due diligence before making any purchase decision. CONTACT: Email: support@wuzutech.com
Phone: (866) 479-1629
Anteris Reports 2025 Financial Results and Provides Corporate Update
MINNEAPOLIS and BRISBANE, Australia, Feb. 26, 2026 (GLOBE NEWSWIRE) — Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the full year ended December 31, 2025, and provided a corporate update. 2025 Full Year Highlights & Recent Developments Initiated the global pivotal PARADIGM Trial, building on experience from successfully treating 130 patients with the DurAVR® THV, including de novo (first time) aortic stenosis cases, complex anatomies and valve-in-valve patientsReceived FDA Investigational Device Exemption (“IDE”) approval in the fourth quarter of 2025 to initiate the PARADIGM Trial in the United StatesReported favorable 30-day (100 patients) and 1-year (65 patients) DurAVR® THV clinical outcomes from rolling cohorts of small annuli, symptomatic severe aortic stenosis patientsCompleted the first “double DurAVR®” implant in a patient receiving a valve-in-valve replacement in both the mitral and aortic valve positionsStrengthened operational infrastructure and advanced quality management system buildout while advancing manufacturing scale-up to support clinical activities, including ISO 13485 certification for DurAVR® THV productionAppointed David Roberts and Gregory Moss to serve as two new independent directors on the Board of DirectorsReceived approval from the Company’s stockholders for ASX Limited’s grant to the Company of a waiver from ASX Listing Rule 7.1Completed aggregate capital raises totalling $320 million in early 2026, including a strategic investment from Medtronic, plc to support execution of the PARADIGM Trial and advance the Company toward global commercialization of the DurAVR® THV System “2025 was a pivotal year for Anteris, advancing DurAVR® with disciplined execution, strengthening our clinical foundation, and positioning the company for long term leadership in structural heart. We converted strategy into measurable progress, reinforcing our competitive position and accelerating our path toward commercial readiness. The progress achieved in 2025 has strengthened our foundation and sharpened our trajectory toward becoming a leader in next-generation TAVR. We remained focused on what matters most; advancing clinical evidence, strengthening our balance sheet, and building sustainable long-term value,” said Wayne Paterson, Vice Chairman and Chief Executive Officer of Anteris. 2025 Financial Results The financial results for Anteris for the year ended December 31, 2025, are presented below. The Company’s net operating cash outflows for the year ended December 31, 2025, were $77.8 million, in line with the increase in clinical, regulatory and manufacturing requirements to support the PARADIGM Trial. Reflecting this clinical focus, the key areas of the Company’s operating expenditures for the year ended December 31, 2025, were as follows: R&D expenses were $69.1 million and included the upscaling of manufacturing and quality capabilities, including process design and validation activities, an increase in R&D headcount, PARADIGM Trial preparatory activities, including clinical costs associated with the enrolment of additional patients and the scaling of our field-based clinical team, and expansion of our medical affairs activities, partially offset by lower DurAVR® THV product research costs as we shifted our focus to clinical, regulatory and manufacturing activities ahead of the PARADIGM Trial.Selling, general and administrative expenses were $26.1 million. Anteris refers to the detailed financial information contained in its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, including the discussion under the headings “Item 1A. Risk Factors” and “Item 7. Management’s Discussion & Analysis of Financial Condition and Results of Operations.” About the PARADIGM Trial The PARADIGM Trial is a prospective randomized controlled trial which will evaluate the safety and effectiveness of the DurAVR® THV compared to commercially available transcatheter aortic valve replacements (“TAVRs”). This head-to-head study will enroll approximately 1000 patients in the ‘All Comers Randomized Cohort’ with 1:1 randomization of patients who will receive either the DurAVR® THV or TAVR using commercially available and approved THVs. The PARADIGM Trial will assess non-inferiority on a primary composite endpoint of all-cause mortality, all stroke and cardiovascular hospitalization at one year post procedure. The PARADIGM Trial is actively recruiting with the first patients enrolled and implanted during the fourth quarter of 2025. For further information, please refer to ClinicalTrials.gov NCT07194265. About Anteris Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients. Anteris’ lead product, the DurAVR® Transcatheter Heart Valve (“THV”), was designed in collaboration with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System. Forward-Looking Statements This announcement contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under “Risk Factors” in Anteris’ Annual Report on Form 10-K for the fiscal period ended December 31, 2025 that was filed with the Securities and Exchange Commission and ASX. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Anteris does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations. For more information: Global Investor Relationsinvestors@anteristech.comDebbie OrmsbyAnteris Technologies Global Corp.+61 1300 550 310 | +61 7 3152 3200Investor Relations (US)mchatterjee@bplifescience.comMalini Chatterjee, Ph.D.Blueprint Life Science Group+1 917 330 4269 Websitewww.anteristech.com X@AnterisTech LinkedInhttps://www.linkedin.com/company/anteristech
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Announced positive topline results from TX45 Phase 1b acute hemodynamic clinical trial in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH-HFrEF”) in October 2025. Topline results showed TX45 was well tolerated and improved both left heart function and pulmonary hemodynamics in patients with Group 2 PH-HFrEFTX2100 advanced into Phase 1a healthy volunteer clinical trial, randomizing the first subject in February 2026, as a potential treatment for Hereditary Hemorrhagic Telangiectasia (“HHT”)TX45 advanced into Phase 2 clinical trial in February 2026 with first site activated and opened for screening patients with Pulmonary Hypertension associated with Interstitial Lung Disease (“PH-ILD”, Group 3 PH) to potentially broaden the therapeutic scope of TX45Announced the appointment of François Nader, M.D., MBA, as an independent director to Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the BoardTX45 APEX Phase 2 clinical trial topline results expected in 2026 in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”)Cash and cash equivalents were approximately $253.8 million as of December 31, 2025, expected to provide cash runway into Q4 2028 WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) — Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided an overview of recent business highlights. “Over the last 12 months, we have made significant progress expanding our clinical pipeline. In February 2026 we advanced our second program, TX2100, a potential novel treatment for patients with HHT, and dosed the first patient in a Phase 1a clinical trial in normal healthy volunteers. This marks an important milestone for Tectonic which now has two programs in clinical development to address patient populations with high unmet need and no approved therapy,” said Alise Reicin, M.D., President and Chief Executive Officer of Tectonic Therapeutic. “We continued to advance TX45 through a series of important clinical and operational milestones, and we expect topline results from our ongoing APEX Phase 2 clinical trial in PH-HFpEF patients in 2026. Furthermore, in February 2026, Tectonic initiated its second TX45 Phase 2 clinical trial to evaluate TX45 in patients with PH-ILD.” Recent Business Highlights Positive Topline Results from Part B of the TX45 Phase 1b Clinical Trial: In October 2025, Tectonic announced positive topline results from Part B of the TX45 Phase 1b clinical trial in 14 patients with Group 2 PH-HFrEF. TX45 was well tolerated and demonstrated a 29.2% reduction in pulmonary capillary wedge pressure (“PCWP”) and a 17.3% improvement in cardiac output. In the subpopulation with combined pre- and post-capillary pulmonary hypertension (“CpcPH”), who have elevated pulmonary vascular resistance (“PVR”) and more severe disease, TX45 also demonstrated reductions in PVR.TX2100 HHT Phase 1a Healthy Volunteer Clinical Trial Randomized First Subject in February 2026: TX2100 is a VHH-Fc fusion antagonist antibody that binds to the APJ receptor (also known as the apelin receptor; APLNR), a GPCR that mediates signaling by the pro-angiogenic peptide hormone apelin. TX2100 is being developed as a potential therapy for HHT, the second most common inherited bleeding disorder affecting an estimated 75,000 people in the United States. In February 2026, Tectonic randomized the first subject in the randomized, placebo-controlled, double-blind ascending-dose Phase 1a clinical trial in normal healthy volunteers. Primary endpoints include safety and tolerability, with secondary endpoints evaluating pharmacokinetics.TX45 PH-ILD Phase 2 Clinical Trial Opened for Screening in February 2026: PH-ILD (Group 3 pulmonary hypertension) is a rare disease characterized by limited therapeutic options and high mortality. In February 2026, the first site was activated and opened for screening in the 16-week, open-label, repeat-dose Phase 2 clinical trial to evaluate TX45’s safety and hemodynamic effects in up to 25 patients. The clinical trial will initiate at a 300 mg dose of TX45 administered subcutaneously every four weeks, with the primary efficacy endpoint defined as change from baseline in PVR at Week 16. TX45 is designed to target multiple components of PH-ILD pathophysiology, including pulmonary vasodilation, anti-inflammatory activity, vascular remodeling and anti-fibrotic effects.Hosted Key Opinion Leader (KOL) Webinar: In February 2026, Tectonic hosted a virtual KOL event featuring Hanny Al-Samkari, MD (Massachusetts General Hospital, Harvard Medical School), who joined Tectonic’s Chief Scientific Officer to discuss the unmet medical need, clinical context, and therapeutic rationale for TX2100 in Hereditary Hemorrhagic Telangiectasia (HHT), including the target, mechanistic rationale and supporting preclinical evidence. A replay of the webinar can be accessed here. Upcoming Milestones Ongoing TX2100 Phase 1a Clinical Trial Topline Results Expected in Q4 2026: Tectonic expects topline results for the Phase 1a clinical trial of TX2100 in healthy volunteers in the fourth quarter of 2026. Assuming adequate safety and PK are established, Tectonic plans to initiate a Phase 2 proof-of-concept clinical trial in moderate to severe HHT patients with frequent epistaxis and anemia in early 2027. The goal of the trial will be to evaluate improvement in epistaxis, anemia, hematological support, and other HHT endpoints. Tectonic is also planning a Phase 1b clinical trial to explore the safety and efficacy (epistaxis, anemia, and hematological support) of TX2100 in patients with severe HHT.Ongoing TX45 APEX Phase 2 Clinical Trial Topline Results Expected in 2026: The global, randomized, placebo-controlled 24-week APEX Phase 2 clinical trial is evaluating the safety and efficacy of subcutaneous TX45 in patients with PH-HFpEF, enriched for CpcPH. The primary endpoint is change from baseline in PVR in the CpcPH population with PVR ≥3 Wood Units, with approximately 70% of enrolled patients targeted to meet the enriched criteria. APEX Phase 2 topline results are expected in 2026. Overview of Financial and Operating Results Cash Position: As of December 31, 2025, cash and cash equivalents were $253.8 million, compared to $268.4 million as of September 30, 2025. Tectonic anticipates that, based on current operating assumptions, its current cash and cash equivalents will provide a cash runway into Q4 2028, including through the Phase 2 readout for TX45 in PH-HFpEF and PH-ILD, and the progression of TX2100 for HHT into clinical development.Research and Development Expenses: Research and development expenses were $16.3 million for the three months ended December 31, 2025, as compared to $9.2 million for the three months ended December 31, 2024. The increase was primarily the result of CRO costs related to the ongoing Phase 2 clinical trial of TX45 and employee-related expenses due to an increase in non-cash, stock-based compensation expense.General and Administrative Expenses: General and administrative expenses were $5.2 million for the three months ended December 31, 2025, as compared to $4.8 million for the three months ended December 31, 2024. Net Loss: For the three months ended December 31, 2025, Tectonic had a net loss of $19.2 million compared to a net loss of $12.4 million for the three months ended December 31, 2024. About Group 2 Pulmonary Hypertension in HFpEFThe World Health Organization has defined 5 groups of pulmonary hypertension (“PH”). Tectonic is focused on the Group 2 subtype, a condition that develops due to left-sided heart disease, specifically PH-HFpEF. In patients with PH-HFpEF, chronic heart failure leads to increased blood pressure in the pulmonary arteries, exerting severe strain on the right side of the heart, which adapts poorly to the increased pressure. This increased pulmonary pressure gradually causes worsening exercise capacity, shortness of breath and right-sided heart failure, which can lead to death. PH-HFpEF is further segmented based on pulmonary hemodynamics into Isolated, post-capillary PH (“IpcPH”) and CpcPH. CpcPH is more severe, accounts for about one third to one half of the 1.4 million PH-HFpEF patients in the U.S. and is characterized by additional, abnormal changes to the pulmonary vasculature, leading to an increase in PVR. Although several Group 1 PH (Pulmonary Arterial Hypertension, “PAH”) medications have been explored in Group 2 PH, to date, no medications have been approved for its treatment. About Group 3 Pulmonary Hypertension and PH-ILDGroup 3 is PH due to chronic lung disease and Tectonic is focused on a Group 3 subtype, called PH-ILD where PH develops in patients who have ILD. ILD is a group of rare conditions causing inflammation and scarring in the lungs. It is believed that a combination of factors leads to the formation of PH-ILD, including lung fibrosis, chronic hypoxia, vascular remodeling and other factors that lead to worsening exercise capacity. PH-ILD has worse survival than ILD without PH. There are currently two approved treatments for PH-ILD, both of which contain the active ingredient treprostinil administered via nebulizer or dry powder inhaler. About TX45, a long-acting Fc-relaxin fusion proteinTX45 is an Fc-relaxin fusion protein with optimized pharmacokinetics and biophysical properties that activates the RXFP1 receptor, the G-protein coupled receptor target of the hormone relaxin. Relaxin is an endogenous protein, expressed at low levels in both men and women that is a pulmonary and systemic vasodilator with lusitropic, anti-fibrotic and anti-inflammatory activity. In normal human physiology, relaxin is upregulated during pregnancy where it exerts vasodilative effects, reduces systemic and pulmonary vascular resistance and increases cardiac output to accommodate the increased demand for oxygen and nutrients from the developing fetus. Relaxin also exerts anti-fibrotic effects on pelvic ligaments to facilitate delivery of the baby. About Hereditary Hemorrhagic Telangiectasia (HHT)HHT is a rare, inherited vascular disorder affecting an estimated 75,000 people in the United States. HHT is the second most common inherited bleeding disorder and a disease for which there are currently no approved therapies. It is characterized by fragile, abnormal blood vessels that lead to recurrent bleeding, which can reduce quality of life, result in emergency room visits and hospitalizations, as well as chronic anemia requiring frequent iron infusions and/or blood transfusions. Many patients with HHT also develop arteriovenous malformations (AVMs) in vital organs such as the lungs, brain, and liver that, if left untreated, are at risk of rupturing and can result in serious and potentially life-threatening complications including lung or brain hemorrhage, stroke, heart failure, or death. Despite being a rare disease and the second most common inherited bleeding disorder, there are currently no approved therapies. About TX2100, a VHH-Fc fusion antagonist antibodyTX2100, is a VHH-Fc fusion antagonist antibody that binds to the APJ receptor (also known as the apelin receptor; APLNR), a GPCR that mediates signaling by the pro-angiogenic peptide hormone apelin. APJ represents a differentiated approach for the potential treatment of HHT. APJ is a selective anti-angiogenic target that is primarily expressed in endothelial cells and is generally quiescent under normal physiological conditions, but is upregulated during pathologic angiogenesis, including in HHT preclinical models.TX2100 is designed as a selective APJ antagonist intended to inhibit disease-associated angiogenic signaling with the goal of providing a more favorable safety profile compared to less selective anti-angiogenic approaches. Anti-angiogenic agents have demonstrated activity in HHT preclinical models and in patients, and APJ antagonism has shown activity in multiple HHT preclinical models, supporting development of TX2100 for this indication. About TectonicTectonic Therapeutic is a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Leveraging its proprietary technology platform called GEODe™ (GPCRs Engineered for Optimal Discovery), Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Tectonic focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life. Tectonic is headquartered in Watertown, Massachusetts. For more information, please visit www.tectonictx.com and follow @TectonicTx on X (formerly Twitter) and LinkedIn. Forward-Looking StatementsThis press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are “forward-looking statements.” These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the design, objectives, initiation, timing, progress and results of current and future preclinical studies and clinical trials of Tectonic’s product candidates, including the ongoing Phase 2 clinical trials for its lead product candidate, TX45, in Group 2 PH-HFpEF and in Group 3 PH-ILD and the ongoing Phase 1 clinical trial for TX2100; and the Company’s expected cash runway. These forward-looking statements are based on Tectonic’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Tectonic’s clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the impacts of macroeconomic conditions, including the conflict in Ukraine and the conflict in the Middle East, heightened inflation and uncertain credit and financial markets, on Tectonic’s business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; Tectonic’s ability to realize the benefits of its collaborations and license agreements; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation or other disputes. Other factors that may cause Tectonic’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified under the heading “Risk Factors” in Tectonic’s annual report on Form 10-K filed for the year ended December 31, 2025 and in other filings that Tectonic makes and will make with the SEC in the future. Tectonic expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. Contacts: Investors:Dan FerryLifeSci Advisorsdaniel@lifesciadvisors.com(617) 430-7576 Media:Kathryn MorrisThe Yates Networkkathryn@theyatesnetwork.com(914) 204-6412 Tectonic Therapeutic, Inc.Consolidated Statements of Operations and Comprehensive Loss(in thousands, except share and per share data) Three Months Ended December 31, Year Ended December 31, 2025 2024 2025 2024 (unaudited) Operating expenses: Research and development $16,341 $9,155 $63,489 $41,364 General and administrative 5,175 4,834 20,547 16,651 Total operating expenses 21,516 13,989 84,036 58,015 Loss from operations (21,516) (13,989) (84,036) (58,015)Other income (expense), net: Change in fair value of SAFE liabilities — — — (3,610)Interest income 2,564 1,735 11,297 4,261 Interest expense (12) (23) (63) (107)Other expense (8) (96) (119) (511)Total other income (expense), net 2,544 1,616 11,115 33 Loss before income tax (18,972) (12,373) (72,921) (57,982)Income tax expense (254) — (1,230) — Net loss (19,226) (12,373) (74,151) (57,982)Other comprehensive loss: Foreign currency translation adjustment (21) 83 (105) 9 Comprehensive loss $(19,247) $(12,290) $(74,256) $(57,973)Net loss per share, basic and diluted $(1.03) $(0.84) $(4.05) $(6.83)Weighted-average common shares outstanding, basic and diluted 18,718,209 14,729,618 18,322,533 8,490,171 Tectonic Therapeutic, Inc.Select Condensed Consolidated Balance Sheet Data(in thousands)(unaudited) December 31, 2025 December 31, 2024 Cash and cash equivalents $253,798 $141,239Working capital* 247,693 135,247Total assets 261,038 152,905Total stockholders’ equity 251,329 140,776 *Working capital is defined as current assets less current liabilities



